Compare Thomson Reuters Corp (TRI) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Thomson Reuters Corp vs State Street SPDR S&P Biotech ETF — how do they compare? Thomson Reuters Corp trades at $101.45 (market cap $43.89B), while State Street SPDR S&P Biotech ETF trades at $149.99 (market cap $10.11B). The key difference: Thomson Reuters Corp is far larger — about 4.3× State Street SPDR S&P Biotech ETF's market cap, and Thomson Reuters Corp pays a 2.58% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Thomson Reuters Corp for 63 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| TRI | XBI | |
|---|---|---|
Market Cap | $43.89B | $10.11B |
Volume | 1,648,199 | 12,903,266 |
Sector | Industrials | Broad Market / Factor |
52-Week High | $163.45 | $169.55 |
52-Week Low | $76.55 | $104.99 |
Typical Hold Time | 63 Days | 37 Days |
Enterprise Value | $46.51B | — |
Dividend Yield | 2.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Thomson Reuters (TRI) trades at $99.28, up 1.21% today, with strong technical momentum and bullish moving average signals. The company demonstrates solid fundamentals with 10% organic growth in core businesses and a 21.22% net income margin. Recent strategic moves include divesting its print unit to focus on technology offerings and launching its proprietary AI model, positioning for future growth.
TRI presents a compelling investment case with analyst consensus targeting $133.25 (34% upside) and strong institutional support. However, risks include recent cybersecurity incidents and margin compression from 2023 peaks. The company's shift toward AI and recurring revenue models supports long-term growth potential despite near-term execution challenges.
XBI trades at $150.23, down 0.44% on the day, with a bearish technical signal driven by moving averages and oscillators. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts. Recent news highlights sector optimism from cancer vaccine breakthroughs and improved capital access, though the ETF carries higher volatility than broader healthcare funds.
The outlook is mixed: strong sector tailwinds from innovation and consolidation support growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst sentiment is neutral with 100% hold ratings, suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Thomson Reuters Corp
Thomson Reuters is the result of the $17.6 billion megamerger of Canada's Thomson and the United Kingdom's Reuters Group in 2008 and the 2018 carve-out of its finance and risk business, Refinitiv, in which it holds a 45% stake. In 2019, the company agreed to exchange its 45% stake in Refinitiv for a 15% stake in LSE, which closed in early 2021. Since the divestiture, the company is more concentrated on selling its flagship legal data and software, Westlaw, and its tax accounting software, Onesource. Reuters sees roughly 80% of revenue and 70% of expenses attributed to the United States, while the remainder (largely through the global print and Reuters News segments) is distributed across Latin America, Europe, the Middle East, Africa, and Asia-Pacific.
Read more on TRI →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
